Hepatitis C News and Research

Latest Hepatitis C News and Research

Media examine floods' impact in Pakistan

News outlets reported on the effects of major flooding in Pakistan and described the situation on the ground.

2 Sep 2010

Greater clarity on legal implications of testing incapacitated patients for blood-borne viruses needed

Anaesthetists are calling for greater clarity on the legal implications of testing incapacitated patients for blood-borne viruses, after a survey found that this is often done following staff needlestick injuries, in possible breach of UK legislation.

31 Aug 2010

Revolutions Medical seeks due recognition for RevVac vacuum operated auto retractable safety syringe

Revolutions Medical Corporation has notified the MDEA that there had been an error in awarding the Free Vac syringe the 2010 Medical Design Excellence Award when in fact Free Vac misrepresented ownership of the syringe. The syringe was actually Revolutions Medical Corporation's RevVac auto retractable safety syringe.

30 Aug 2010

Biomagnetics to acquire Lanzhou New Sunshine Plastics Industry

Biomagnetics Diagnostics Corp., a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis and malaria detection, and other innovative technologies, today announced the signing of a Letter of Intent (LOI) with Lanzhou New Sunshine Plastics Industry LTD. This expected acquisition is the fourth planned acquisition targeted at a share price of US $1.50 for Biomagnetics Diagnostics' common shares.

30 Aug 2010

Biomagnetics Diagnostics to acquire Hubei Tianyuan Chemical

Biomagnetics Diagnostics Corp., a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis and malaria detection, and other innovative technologies, today announced the signing of a Letter of Intent (LOI) with Hubei Tianyuan Chemical Co., Ltd. of Yangxin Nacheng Chemical Industry Zone, located in Hubei Province, China.

27 Aug 2010

FDA accepts Sanofi Pasteur's Menactra vaccine sBLA for active immunization of infants and toddlers

Sanofi Pasteur, the vaccines division of the sanofi-aventis Group, announced today that the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental Biologics License Application (sBLA) for use of Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) for active immunization of infants and toddlers for the prevention of invasive meningococcal disease caused by serogroups A, C, Y, and W-135.

26 Aug 2010

ZymoGenetics completes enrollment in Phase 2b PEG-IFN lambda clinical trial

ZymoGenetics, Inc. today announced enrollment has been completed in the Phase 2b clinical trial with PEG-Interferon lambda and ribavirin in chronic hepatitis C virus (HCV) infection.

25 Aug 2010

Pharmasset commences dosing in PSI-7977 Phase 2b study for chronic hepatitis C

Pharmasset, Inc. announced today that dosing has begun in a Phase 2b study of PSI-7977, a nucleotide analog polymerase inhibitor for the treatment of chronic hepatitis C (HCV). The trial will evaluate PSI-7977 200mg QD and 400mg QD in combination with pegylated interferon alfa 2a and ribavirin, the current standard of care (SOC) in patients with HCV genotype 1 who have not been treated previously.

24 Aug 2010

Medivir appoints Daewoong as South Korean distributor for Xerclear

Medivir AB today announced it has appointed Daewoong Pharmaceutical Co. Ltd. as its exclusive distributor for Xerclear™ in South Korea. Under the terms of the agreement, Daewoong will be responsible for obtaining the regulatory approvals, and for marketing, sales and distribution of Medivir's cold sore product in the territory. In consideration of the rights granted to Daewoong, Medivir will receive upfront and milestone payments and royalties on sales according to a profit sharing scheme.

24 Aug 2010

LabCorp launches IL-28B gene test for HCV infection

Laboratory Corporation of America® Holdings announced today the nationwide availability of a genetic test to detect the presence of a single polymorphism within the IL-28B gene that has been reported to help predict a person's response to certain hepatitis C virus (HCV) therapies.

24 Aug 2010

Hepatitis E vaccine successful in clinical trial: Study

In a Clinical trial in China, a vaccine has been found to protect against Hepatitis E. Hepatitis E virus, usually spread via contaminated food and faeces usually runs its course before the patient recovers. However it can cause severe illness in elderly people and has a mortality rate of 1 to 3 percent. It can also kill 5 to 25 percent of affected pregnant women and those who survive can suffer high rates of miscarriage. Around a third of the world's population have been infected by the virus say researchers.

22 Aug 2010

FDA extends review on Acetadote for non-acetaminophen acute liver failure

Cumberland Pharmaceuticals Inc. today announced the U.S. Food and Drug Administration (FDA) has extended its review of the supplemental new drug application (sNDA) for the use of Acetadote® (acetylcysteine) Injection in patients with non-acetaminophen acute liver failure.

21 Aug 2010

Broadband could be boon for rural clinics

A federal broadband initiative may have implications for the health system, too, NPR reports. "Millions of Americans who live in rural areas travel long distances to get health care. Or they may go without it. But high-speed Internet connections now make it possible to bring a doctor's expertise to patients in far-off places, if those places are connected. As part of its National Broadband Plan, the Federal Communications Commission has pledged $400 million a year to connect nearly 12,000 rural health care providers."

19 Aug 2010

Achillion Pharmaceuticals enters agreement to raise $50.1 million from sale of common stock

Achillion Pharmaceuticals, Inc., a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that it has entered into definitive agreements for the purchase of $50.1 million of Achillion's common stock and warrants in a private placement financing with a select group of institutional and accredited investors, namely Domain Associates, Clarus Ventures, Quaker BioVentures and Pappas Ventures.

19 Aug 2010

BBC reports on efforts to broaden access to childhood vaccines

The BBC reports on discussions about childhood immunization at the International Pediatric Association (IPA) meeting last week in Johannesburg, South Africa. "Vaccines are a key plank in meeting Millennium Development Goal 4 - to reduce child mortality by two thirds by 2015 - and many sessions at the congress were devoted to them," the news service writes.

18 Aug 2010

World Bank to provide $900M in emergency funding for Pakistan floods, country's High Commissioner provides rough damage estimate

The World Bank on Monday "pledged to reroute money from other projects to provide $900 million in emergency funding to help Pakistan" with its flood recovery efforts, the New York Times reports (Ellick, 8/17).

18 Aug 2010

Pharmacists in all states authorized to administer influenza vaccines

The American Pharmacists Association (APhA) is encouraging consumers to get immunized against influenza and to consider their local pharmacy as the site to receive their vaccine. Pharmacists in all 50 states including the District of Columbia are authorized to administer influenza vaccines and, as of June 30, 2010, more than 120,000 U.S. pharmacists have been trained to administer immunizations.

18 Aug 2010

Long-term entecavir therapy suppresses HBV DNA, normalizes ALT and improves liver histology

Researchers from this international study found that patients with chronic hepatitis B virus (HBV) infection who received at least 3 years of cumulative entecavir (antiviral) therapy achieved substantial histologic improvement and regression of fibrosis or cirrhosis. Full details of the study appear in the September issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases (AASLD).

18 Aug 2010

Long-term Entecavir therapy reverses fibrosis and cirrhosis in chronic hepatitis B patients

17 Aug 2010

Hepatitis C rather than Donor Risk Index is major contributor to poor graft survival in transplant patients

The Donor Risk Index, which assesses donor characteristics impacting liver transplantation outcomes, does not bear the same impact on outcomes on a small scale as is suggested from large-scale, national data.

17 Aug 2010

Hepatitis C News and Research

Latest Hepatitis C News and Research

Media examine floods' impact in Pakistan

Greater clarity on legal implications of testing incapacitated patients for blood-borne viruses needed

Revolutions Medical seeks due recognition for RevVac vacuum operated auto retractable safety syringe

Biomagnetics to acquire Lanzhou New Sunshine Plastics Industry

Biomagnetics Diagnostics to acquire Hubei Tianyuan Chemical

FDA accepts Sanofi Pasteur's Menactra vaccine sBLA for active immunization of infants and toddlers

ZymoGenetics completes enrollment in Phase 2b PEG-IFN lambda clinical trial

Pharmasset commences dosing in PSI-7977 Phase 2b study for chronic hepatitis C

Medivir appoints Daewoong as South Korean distributor for Xerclear

LabCorp launches IL-28B gene test for HCV infection

Hepatitis E vaccine successful in clinical trial: Study

FDA extends review on Acetadote for non-acetaminophen acute liver failure

Broadband could be boon for rural clinics

Achillion Pharmaceuticals enters agreement to raise $50.1 million from sale of common stock

BBC reports on efforts to broaden access to childhood vaccines

World Bank to provide $900M in emergency funding for Pakistan floods, country's High Commissioner provides rough damage estimate

Pharmacists in all states authorized to administer influenza vaccines

Long-term entecavir therapy suppresses HBV DNA, normalizes ALT and improves liver histology

Long-term Entecavir therapy reverses fibrosis and cirrhosis in chronic hepatitis B patients

Hepatitis C rather than Donor Risk Index is major contributor to poor graft survival in transplant patients

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Hepatitis C News and Research

Latest Hepatitis C News and Research

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in